BALTIMORE, Aug. 12, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has initiated research coverage of ChromaDex Corporation (OTCBB:CDXC), a leading phytochemical and botanical reference standards provider and innovative product developer in the nutraceutical industry.
ChromaDex is widely considered to be the current gold standard for the quality control of natural products and management has diversified its revenue stream by creating or licensing IP in the space and introducing novel and innovative natural products with health benefits that serve huge markets.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.
"ChromaDex's status gives it a unique opportunity to introduce next generation natural products to the food/beverage, cosmetic and other industries that represent huge markets. We believe it's a great way to invest in a leader in the nutraceutical market at a compelling valuation. Plus, having the Chairman of Teva Pharmaceutical (Nasdaq:TEVA) participate as a large, active investor in the Company validates the Company's business model and helps ensure long-term success," Goldman commented.
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer. To download our research, disclosures, or for more information, visit www.goldmanresearch.com.
About ChromaDex Corporation.: ChromaDex Corporation (OTCBB:CDXC) is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical, pharmaceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. With exclusive worldwide patent rights for pterostilbene , the Company is currently focusing on clinical studies and the commercialization of its new product, pTeroPure™.
For more information and disclosures, visit www.chromadex.com.